Clinical Trial

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Study acronym: CHIPRO
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-09; most recent amendment 2024-10-17.
Status change: Not Yet Recruiting → Recruiting 2022-03-07
Trial Details
NCT Number NCT04921527
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel
Enrollment 454 participants
Start Date 2021-12-20
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-18